Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CPB1 | P15086 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029567 | 1.00 | TSHR (0.57) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL5029572 | 1.00 | TSHR (0.57) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL6027318 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL6182604 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL7114434 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL3744086 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL417696 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL13198668 | 0.89 | ALDH1A1 (0.56) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL4261374 | 0.87 | ALDH1A1 (0.58) | TSHRCPB1ALDH1A1GAAEPHX1 | |
| SCHEMBL4261378 | 0.87 | ALDH1A1 (0.58) | TSHRCPB1ALDH1A1GAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | TSHR 1726/4885CPB1 764/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.